Convalescent plasma in patients receiving rituximab or ocrelizumab for multiple sclerosis or neuromyelitis Optica spectrum disorder with Covid-19: A multicenter retrospective study

Background: Despite vaccination, patients receiving anti-CD20 monoclonal antibodies (mAbs) for multiple sclerosis (MS) or neuromyelitis optica spectrum disorders (NMOSD) have an increased risk of developing severe or protracted COVID-19. The aim of this study was to describe the effect of COVID-19 c...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Tanguy Dequidt, Quentin Richier, Céline Louapre, Florence Ader, Yanis Merad, Nicolas Lauwerier, Christine Jacomet, Michel Carles, Charlotte Biron, Vincent Gendrin, Clément Marlat, François Danion, Tristan M Lepage, Albert Sotto, Loïc Bourdellon, Alexandre Mania, Martin Martinot, Georges Le Falher, Alexis Ferre, Benoit Pilmis, Guillaume Gondran, Pierre Simeone, Matthieu Henry, Toufik Kamel, Simon Ray, Sophie Ancellin, Nicolas Mélé, Fabrice Camou, Marjolaine Destremau, Jeremy Sellenet, Noémie Zucman, Marion Le Maréchal, Khawla Mellouki, Marie-Elodie Langlois, David Luque Paz, Maud Mousset, Catherine Leclerc, Agnès Sommet, Karine Lacombe, Guillaume Martin-Blondel
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2025-02-01
Sarja:	International Journal of Infectious Diseases
Aiheet:	SARS-CoV-2 Protracted COVID-19 Convalescent plasma Anti-CD20 antibodies Multiple sclerosis Neuromyelitis optica
Linkit:	http://www.sciencedirect.com/science/article/pii/S1201971224003989
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!